Download investor and scientific decks.
Financial results, pipeline milestones, and strategic outlook.
Overall survival endpoints from Phase III study in mCRPC.
At Medisafe Therapeutics, we are pioneering radioligand therapies that target cancer cells with precision, minimizing damage to healthy tissue. Our presentations reflect decades of research, clinical excellence, and a commitment to transforming patient outcomes in oncology.
Extensive clinical data demonstrating favorable safety profiles across multiple indications.
Statistically significant improvements in progression-free and overall survival.
Expanding manufacturing to ensure worldwide availability of life-saving therapies.